| Literature DB >> 28711079 |
Tiina Podymow1, Phyllis August2.
Abstract
Chronic hypertension complicates 1% to 5% of all pregnancies, but debate continues regarding the benefits of lowering blood pressure in pregnancy as well as the optimal blood pressure targets. Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks. Severe hypertension (systolic ≥ 160 mm Hg) should be treated, but there is considerable variability in the approach to mild-to-moderate hypertension (140-159/90-109 mm Hg). The recently published CHIPS (Control of Hypertension in Pregnancy Study) trial is an important effort to attempt to determine treatment goals in mild to moderate pregnancy hypertension. The risks and benefits of tight versus less tight control of blood pressure in nonproteinuric hypertensive women, most of whom had pre-existing hypertension, were evaluated. A main finding was an increased risk of severe hypertension (adjusted odds ratio, 1.8) when blood pressure was not tightly controlled. In this review, general management of chronic hypertension in pregnancy is discussed, including changes in treatment that may be appropriate in light of new clinical trial data.Entities:
Keywords: antihypertensives; chronic hypertension; guidelines; hypertension; postpartum hypertension; preeclampsia; pregnancy
Mesh:
Substances:
Year: 2017 PMID: 28711079 DOI: 10.1016/j.semnephrol.2017.05.012
Source DB: PubMed Journal: Semin Nephrol ISSN: 0270-9295 Impact factor: 5.299